Amyloid Precursor Protein (APP)

Pathway / Interaction Diagram

flowchart LR
    N1["Amyloid Precursor Protein (..."]
    N1 -->|"associated with"| N2["Cancer"]
    N1 -->|"associated with"| N3["Neurodegeneration"]
    N1 -->|"activates"| N4["Alzheimer"]
    N1 -->|"therapeutic target"| N4["Alzheimer"]
    N1 -->|"therapeutic target"| N5["Als"]
    N1 -->|"activates"| N5["Als"]
    style N1 fill:#006494,stroke:#333,color:#e0e0e0,stroke-width:2px

Overview

APP](/proteins/app) (APP) is a topic within the NeuroWiki knowledge base covering aspects of neurodegenerative disease research and mechanisms. ^{1Muller UC, Deller T. The physiological functions of sAPPalpha (2017)2017 · PMID 28315828Open reference}

The APP](/proteins/app) (APP) is a transmembrane glycoprotein that plays a central role in the pathogenesis of Alzheimer’s disease (Alzheimer’s disease). As the source of amyloid-beta (amyloid-beta) peptides that form amyloid amyloid plaques in the Alzheimer’s disease brain, APP has been the focus of intensive research since its discovery in 1987. This protein has become one of the most extensively studied molecules in neuroscience due to its central position in the amyloid hypothesis and its broader physiological functions in the nervous system [1]. ^{2APP and synaptic function plasticity (2011)2011 · PMID 21170439Open reference}

Gene and Protein Structure

The APP gene is located on chromosome 21q21.2-21.3 and spans approximately 350 kb. It encodes a type I transmembrane protein with multiple isoforms generated by alternative splicing. The major isoforms contain 770, 751, and 695 amino acids, with APP770 and APP751 being the predominant forms in most tissues, while APP695 is predominantly expressed in neurons [2]. ^{3APP family interactors in neuronal function (2005)2005 · PMID 15878469Open reference}

Chromosomal Location and Genetic Variants

The APP gene resides on the long arm of chromosome 21 at position 21.21, a region that has received particular attention due to the relationship between Down syndrome (trisomy 21) and early-onset Alzheimer’s disease pathology. The gene consists of 18 exons spanning approximately 350 kb of genomic DNA. Alternative splicing of exons 7, 8, and 15 generates the different APP isoforms. ^{4Fe65 and APP signaling (2005)2005 · PMID 15882601Open reference}

Domain Structure

APP consists of several distinct domains [3]: ^{5Metals and amyloid in Alzheimer's disease (2008)2008 · PMID 18221186Open reference}

• N-terminal signal peptide (1-18 aa): Directs protein to the secretory pathway and is cleaved during translocation into the endoplasmic reticulum

• Extracellular domain (19-650 aa): Contains the amyloid-beta sequence within its transmembrane region and mediates most of APP’s physiological functions

• amyloid-beta region (681-770 aa): The amyloid-beta peptide sequence spans residues 681-770 and forms the basis of Alzheimer’s disease pathology

• Transmembrane domain (650-700 aa): Hydrophobic alpha-helix that anchors APP in the cellular membrane

• C-terminal cytoplasmic domain (700-770 aa): Contains sorting motifs and protein interaction domains critical for signaling and trafficking

The extracellular domain contains several functional regions including: ^{6sAPPalpha and neuroprotection (2006)2006 · PMID 16629762Open reference}

• Growth factor-like domain (GFLD, 18-150 aa): Involved in cell growth, survival, and synaptic function function

• Copper-binding domain (CuBD, 124-189 aa): Binds copper ions with high affinity and may participate in oxidative stress regulation [4]

• Kunitz-type protease inhibitor (KPI, 317-370 aa): Present in APP751/770 isoforms, inhibits serine proteases

• Mesenger sequence (MES, 657-670 aa): Internalization signal for endocytosis

APP Family Members

The APP gene family includes [5]: ^{7Karran E, Mercken M, De Strooper B. The amyloid cascade hypothesis (2011)2011 · PMID 21960343Open reference}

• APP: The founding member, 770 amino acids in longest isoform

• APL-1 in C. elegans: Homologous protein with essential developmental functions

• APLP1 (Amyloid Precursor-Like Protein 1): 770 aa, shares 50% homology with APP

• APLP2 (Amyloid Precursor-Like Protein 2): 770 aa, most widely expressed, can compensate for APP loss

All family members share the conserved domain structure but differ in expression patterns and functional roles. Double and triple knockouts of APP family members show embryonic lethality, indicating essential functions. ^{8Selkoe DJ. Resolving controversies on the path to Alzheimer's therapeutics (2011)2011 · PMID 21995349Open reference}

Proteolytic Processing

APP undergoes proteolytic processing through two mutually exclusive pathways [6]: ^{9APP mutations in familial Alzheimer's disease (2017)2017 · PMID 28452453Open reference}

Amyloidogenic Pathway

The amyloidogenic pathway generates amyloid-beta peptides through sequential cleavage by β- and γ-secretases: ^{10APP mutations and amyloid biology (1992)1992 · PMID 1400996Open reference}

1. β-Secretase cleavage (BACE1): The β-site APP cleaving enzyme 1 (BACE1) is an aspartyl protease that cleaves APP at the N-terminus of amyloid-beta (Met81 Asp82), generating a soluble APPβ (sAPPβ) fragment and a C-terminal fragment (CTFβ/β-CTF) [7].

2. γ-Secretase cleavage: The γ-secretase complex is a membrane-embedded aspartyl protease complex consisting of:

   • Presenilin-1 (PSEN1) or Presenilin-2 (PSEN2): Catalytic subunit

   • Aph-1: Stabilizing component

   • Pen-2: Required for activation

   • Nicastrin (NCT): Substrate recognition component

The γ-secretase cleaves CTFβ within the transmembrane domain to release amyloid-beta peptides of varying lengths (Aβ38, Aβ40, Aβ42, Aβ43, Aβ46). ^{2APP and synaptic function plasticity (2011)2011 · PMID 21170439Open reference}0

The predominant amyloid-beta species are: ^{2APP and synaptic function plasticity (2011)2011 · PMID 21170439Open reference}1

• Aβ40: The most abundant (∼90% of total amyloid-beta), found in both amyloid plaques and cerebrospinal fluid

• Aβ42: More aggregation-prone, forms oligomers and fibrils more readily, primarily found in amyloid plaques [8]

• Aβ43: Highly neurotoxic, found in early-onset FAD, seeds aggregation

Non-Amyloidogenic Pathway

The non-amyloidogenic pathway involves α-secretase cleavage within the amyloid-beta sequence [9]: ^{2APP and synaptic function plasticity (2011)2011 · PMID 21170439Open reference}2

1. α-Secretase cleavage: ADAM10 (A Disintegrin And Metalloproteinase domain-containing protein 10) is the major α-secretase. It cleaves APP at residue Lys16-Leu17 of the amyloid-beta sequence (Arg687-Ser688), generating sAPPα and CTFα.

2. γ-Secretase cleavage: CTFα is subsequently cleaved by γ-secretase to release the p3 peptide (Aβ17-40/42), which is non-amyloidogenic and not found in amyloid plaques.

The α-secretase cleavage precludes amyloid-beta formation, making this pathway protective. Importantly, α-secretase activity is stimulated by: ^{2APP and synaptic function plasticity (2011)2011 · PMID 21170439Open reference}3

• Protein kinase C (PKC) activation

• Muscarinic receptor activation

• Growth factors (BDNF, NGF, EGF)

• Cell depolarization

APP Intracellular Domain (AICD)

The γ-secretase cleavage also releases the APP intracellular domain (AICD, 50-60 aa), which can translocate to the nucleus and function as a transcriptional regulator [10]. The AICD interacts with: ^{2APP and synaptic function plasticity (2011)2011 · PMID 21170439Open reference}4

• Fe65 adaptor proteins (Fe65, Fe65L1, Fe65L2)

• Tip60 histone acetyltransferase

• Importin-α nuclear import factor

• Various transcription factors (amyloid-beta, NF-κB)

The AICD has been implicated in regulating expression of genes involved in: ^{2APP and synaptic function plasticity (2011)2011 · PMID 21170439Open reference}5

• Synaptic plasticity (Arc, c-Fos)

• Cellular stress response

• Cholesterol metabolism (ABCA1)

• Apoptosis regulation

Physiological Functions of APP

Beyond its role in Alzheimer’s disease pathogenesis, APP has important physiological functions [11]: ^{2APP and synaptic function plasticity (2011)2011 · PMID 21170439Open reference}6

Synaptic Function and Plasticity

APP is highly expressed in neurons and localizes to synaptic function terminals. It plays crucial roles in [12]: ^{2APP and synaptic function plasticity (2011)2011 · PMID 21170439Open reference}7

• Synapse formation and maintenance during development

• Neuronal viability and axonal outgrowth

• Synaptic plasticity and long-term potentiation (LTP)

• Learning and memory processes

APP knockout mice show: ^{2APP and synaptic function plasticity (2011)2011 · PMID 21170439Open reference}8

• Reduced synaptic function plasticity in hippocampal slices

• Impaired spatial learning in Morris water maze

• Altered exploratory behavior

• Compensatory upregulation of APLP proteins

• Subtle deficits in neuronal migration

Cell Adhesion

APP functions as a cell surface receptor and interacts with [13]: ^{2APP and synaptic function plasticity (2011)2011 · PMID 21170439Open reference}9

• Extracellular matrix proteins (laminin, collagen I, collagen IV)

• Cell adhesion molecules (L1, N-CAM, Ng-CAM)

• Heparan sulfate proteoglycans

• Integrins (α5β1, αvβ3)

These interactions mediate: ^{3APP family interactors in neuronal function (2005)2005 · PMID 15878469Open reference}0

• Neuronal migration during development

• Axonal pathfinding

• Synapse formation and stabilization

• Cell-cell communication

Signal Transduction

The APP intracellular domain (AICD) can function as a transcriptional regulator, interacting with [14]: ^{3APP family interactors in neuronal function (2005)2005 · PMID 15878469Open reference}1

• Fe65 adaptor proteins (mediates nuclear signaling)

• Tip60 histone acetyltransferase (epigenetic regulation)

• Phosphoinositide signaling components

• Various nuclear transcription factors

Metal Ion Homeostasis

APP binds copper (Cu²⁺) and zinc (Zn²⁺) ions with high affinity, potentially playing a role in [15]: ^{3APP family interactors in neuronal function (2005)2005 · PMID 15878469Open reference}2

• Metal ion homeostasis in the brain

• Oxidative stress regulation through Fenton chemistry modulation

• Antioxidant defense mechanisms

• Synaptic transmission and plasticity

Neuroprotection

Soluble APP fragments (sAPPα and sAPPβ) have neurotrophic and neuroprotective effects [16]: ^{3APP family interactors in neuronal function (2005)2005 · PMID 15878469Open reference}3

• sAPPα promotes neurite outgrowth in cultured neurons

• sAPPα enhances neuronal survival against toxic insults

• sAPPα protects against excitotoxicity

• sAPPα modulates synaptic function transmission and plasticity

Developmental Functions

During brain development, APP participates in: ^{3APP family interactors in neuronal function (2005)2005 · PMID 15878469Open reference}4

• Neurogenesis regulation through cell cycle control

• Neuronal migration via interaction with Reelin signaling

• Axonal pathfinding and commissure formation

• Myelination through oligodendrocyte interaction

• Synaptogenesis and pruning

APP in Alzheimer’s Disease

Amyloid Cascade Hypothesis

The amyloid cascade hypothesis, proposed in 1992, posits that amyloid-beta deposition is the initiating event in Alzheimer’s disease pathogenesis [17]. According to this model: ^{3APP family interactors in neuronal function (2005)2005 · PMID 15878469Open reference}5

1. Increased amyloid-beta production or decreased clearance leads to amyloid-beta accumulation

2. amyloid-beta oligomerization and aggregation into amyloid plaques

3. Plaque formation triggers downstream pathological events including:

   • Synaptic dysfunction and loss

   • Neurofibrillary tangle formation (tau pathology)

   • Neuroinflammation

   • Oxidative stress

   • Neuronal and synapse loss

4. Progressive cognitive decline and dementia

While the amyloid cascade hypothesis has dominated Alzheimer’s disease research for decades, clinical trials targeting amyloid-beta have had limited success. This suggests the model may be incomplete or that interventions need to occur much earlier in the disease process, possibly before symptoms appear [18].

Evidence Supporting the Amyloid Hypothesis

• amyloid-beta amyloid plaques are a hallmark pathological feature of Alzheimer’s disease

• APP mutations cause familial Alzheimer’s disease with early onset

• Down syndrome (triple APP) leads to early Alzheimer’s disease pathology

• Aβ42 is more aggregation-prone than Aβ40

• amyloid-beta oligomers are toxic to synapses

• amyloid-beta immunotherapy reduces amyloid plaques and may slow decline

Evidence Challenging the Amyloid Hypothesis

• Many elderly individuals have amyloid plaques but no dementia ( amyloid plaques without dementia)

• Plaque burden does not correlate well with cognitive impairment

• amyloid-beta-targeted therapies have largely failed in clinical trials

• Tau pathology correlates better with cognitive impairment than amyloid-beta

• Neuronal loss precedes significant plaque formation in some cases

APP Mutations and Familial Alzheimer’s disease

Autosomal dominant familial Alzheimer’s disease (FAD) is caused by mutations in APP and the presenilin genes (PSEN1, PSEN2). Over 50 APP mutations have been identified, accounting for approximately 10% of FAD cases [19].

Key APP mutations include:

• Swedish mutation (KM670/671NL): Double mutation at the β-secretase cleavage site, increases amyloid-beta production 3-5 fold

• London mutation (V717I): Valine to Isoleucine at position 717, increases Aβ42/Aβ40 ratio [20]

• Flemish mutation (A692G): Increases amyloid-beta production with enhanced aggregation

• Arctic mutation (E693G): Enhances amyloid-beta protofibril formation

• Iowa mutation (D694N): Promotes amyloid-beta aggregation and plaque formation

• Dutch mutation (E693Q): Hereditary cerebral hemorrhage with amyloidosis - primarily causes CAA

• Italian mutation (E693K): Similar to Dutch, causes hemorrhagic strokes

• Florida mutation (I716T): Increases Aβ42/Aβ40 ratio

• Indiana mutation (V715M): Increases Aβ42/Aβ40 ratio

Down Syndrome (Trisomy 21)

Individuals with Down syndrome have three copies of the APP gene (located on chromosome 21) and invariably develop Alzheimer’s disease-type pathology by age 40-60 [21]. This provides strong evidence that APP overexpression alone is sufficient to cause amyloid-beta accumulation and Alzheimer’s disease-like pathology. Key observations include:

• amyloid-beta deposition begins in the 20s, often before age 30

• Diffuse amyloid plaques appear first in the frontal cortex

• Neuritic amyloid plaques develop in the 30s-40s

• Neurofibrillary tangles develop in parallel with amyloid plaques

• Cognitive decline correlates with neuropathology

• Nearly 100% develop dementia if they live to 60+

amyloid-beta Aggregation and Toxicity

Aggregation Pathway

amyloid-beta peptides undergo a concentration-dependent aggregation process [22]:

1. Monomeric amyloid-beta: Random coil structure, soluble, can be cleared

2. Oligomers: Dimers, trimers, and larger assemblies - most toxic species

3. Protofibrils: Intermediate aggregates, transient species

4. Fibrils: Major component of amyloid amyloid plaques, beta-sheet rich

5. ** amyloid plaques**: Dense-core neuritic amyloid plaques surrounded by dystrophic neurites and glia

Oligomer Toxicity

Soluble amyloid-beta oligomers are now considered the most toxic species [23]:

• Inhibit long-term potentiation (LTP) in hippocampal slices

• Disrupt synaptic function function and reduce spine density

• Cause calcium dysregulation through ion channel effects

• Induce oxidative stress and mitochondrial dysfunction

• Activate glia and chronic neuroinflammation

• Impair axonal transport

• Bind to synapses and remove them

Mechanisms of Toxicity

amyloid-beta exerts toxicity through multiple mechanisms [24]:

• Ion channel formation: amyloid-beta can form ion channels in lipid bilayers

• Receptor interactions: Binds to various neuronal receptors (NMDA, AMPA, insulin receptors, RAGE)

• Oxidative stress: Increases ROS production through metal interaction

• Inflammation: Activates microglia and astrocytes via complement and TLRs

• Synaptic dysfunction: Reduces synaptic function proteins and spine density

Therapeutic Strategies Targeting APP

β-Secretase (BACE1) Inhibitors

BACE1 inhibitors have been extensively investigated as Alzheimer’s disease therapeutics [25]:

• Multiple BACE1 inhibitors entered clinical trials from 2012-2019

• Several failed due to side effects (cognitive worsening, liver toxicity) or lack of efficacy

• The high safety profile requirements for chronic use pose challenges

• Most BACE1 inhibitor programs have been discontinued

Major BACE1 inhibitors tested:

• Verubecestat (MK-8931): Failed in Phase 2/3 for prodromal and mild Alzheimer’s disease

• Lanabecestat (AZD3293): Failed in Phase 3

• Atabecestat (JNJ-54861911): Discontinued due to liver toxicity

• Elenbecestat: Discontinued due to efficacy concerns

γ-Secretase Modulators

Modulators can shift γ-secretase cleavage to produce shorter, less aggregation-prone amyloid-beta species [26]:

• Non-steroidal anti-inflammatory drugs (NSAIDs) showed promise in early trials

• Development has been challenging due to mechanism complexity

• Notebuild, CHF-5074, and others have been tested in clinical trials

Anti-amyloid-beta Immunotherapy

Active and passive immunization approaches have shown some success [27]:

• Active vaccination: AN1792 (first generation) showed promise but was halted due to meningoencephalitis

• Passive antibodies: Several monoclonal antibodies have been tested

• Aducanumab: Received FDA approval in 2021 based on amyloid plaque reduction

• Lecanemab: Received FDA approval in 2023 for early Alzheimer’s disease - showed 27% slower cognitive decline

• Donanemab: Received FDA approval in 2024 - showed 35% slower decline in early Alzheimer’s disease

α-Secretase Activation

Promoting non-amyloidogenic processing [28]:

• PKC activators and muscarinic agonists have been explored

• ADAM10 activation represents a promising approach

• Gene therapy to increase ADAM10 expression is being developed

Direct APP-Targeting Approaches

• Gene therapy to modulate APP expression

• RNA interference to reduce APP

• Small molecules affecting APP trafficking

• APP-specific antibodies and vaccines

APP Processing and Lipid Rafts

APP processing occurs in specific membrane microdomains called lipid rafts [29]:

• β- and γ-secretase activities are enriched in lipid rafts

• α-secretase activity occurs primarily in non-raft regions

• Raft localization influences the processing pathway

• Cholesterol and lipid homeostasis affect APP processing

Lipid raft composition:

• High in cholesterol and sphingolipids

• Contain specific phospholipids like sphingomyelin

• Form detergent-resistant membranes at 4°C

• Concentrate signaling molecules and receptors

APP in Other Neurodegenerative Diseases

While APP is most closely associated with Alzheimer’s disease, it plays roles in other conditions:

Cerebral Amyloid Angiopathy (CAA)

amyloid-beta deposits in cerebral blood vessel walls [30]:

• Primarily Aβ40

• Causes hemorrhagic strokes and cognitive decline

• Common in Alzheimer’s disease and can occur independently

• CAA affects 20-40% of Alzheimer’s disease patients

Traumatic Brain Injury (TBI)

TBI increases APP expression and amyloid-beta accumulation [31]:

• May contribute to post-traumatic neurodegeneration

• Chronic traumatic encephalopathy involves APP/amyloid-beta pathology

• Military veterans with blast exposure show increased APP

Other Conditions

• Amyotrophic lateral sclerosis (ALS): Elevated APP in motor neurons

• Parkinson’s disease: Some amyloid-beta co-localization with Lewy bodies

• Huntington’s disease: Altered APP processing

• Multiple sclerosis: Role in demyelination and repair

APP Interacting Proteins

APP interacts with numerous proteins involved in various cellular processes [32]:

Biomarkers and APP

APP and its cleavage products serve as important biomarkers [33]:

• sAPPα: CSF biomarker reflecting α-secretase activity

• sAPPβ: CSF biomarker reflecting β-secretase activity

• Aβ40: CSF biomarker, most abundant amyloid-beta species

• Aβ42: CSF biomarker, lower in Alzheimer’s disease due to plaque deposition

• Aβ42/Aβ40 ratio: Improved diagnostic accuracy for Alzheimer’s disease

• APP mutations: Genetic testing for familial Alzheimer’s disease

• sAPPβ/α ratio: May indicate β-secretase vs α-secretase activity

Research Tools and Models

Cell Lines

• CHO cells expressing APP wild-type and mutants

• HEK293 cells with APP mutations

• Neuronal cell lines (SH-SY5Y, PC12)

• Induced neurons (iNs) from patient fibroblasts

• Human iPSC-derived neurons

Animal Models

• APP transgenic mice (APP/PDAPP, Tg2576, 3xTg-Alzheimer’s disease, APP/PS1)

• APP knock-in models (avoid overexpression artifacts)

• APP knockout mice (viable, with subtle deficits)

• APP/PSEN1 double transgenic models

• 5xFAD model (5 Alzheimer’s disease mutations)

• CRND8, ArcAD, and other models

In Vitro Systems

• Cell-free γ-secretase assays

• Synthetic amyloid-beta peptides (multiple lengths)

• Recombinant APP fragments

• CRISPR-edited cell lines

• Organoids and brain-on-chip systems

APP Trafficking

APP trafficking is tightly regulated and affects processing [34]:

Intracellular Trafficking

• Endoplasmic reticulum: Initial synthesis and quality control

• Golgi apparatus: Post-translational modification (glycosylation)

• Trans-Golgi network (TGN): Major site of processing

• Plasma membrane: Surface expression and interaction

• Endosomes: β-secretase cleavage occurs here (pH-dependent)

• Lysosomes: Final degradation of fragments

Sorting Motifs

The APP cytoplasmic domain contains:

• YTSI sorting motif for endocytosis

• YENPTY motif for basolateral targeting

• Phosphorylation sites (Thr654) regulating trafficking

Interaction with Sortilin

• SorLA (sortilin-related receptor) binds APP

• Reduces amyloidogenic processing

• GWAS identified SORL1 variants as Alzheimer’s disease risk factors

Cholesterol and APP

Cholesterol metabolism directly affects APP processing [35]:

• High cholesterol increases amyloid-beta production in neurons

• Statins may reduce Alzheimer’s disease risk through cholesterol-independent effects

• Cholesterol-lowering in midlife correlates with lower Alzheimer’s disease risk

• ABCA1 and ABCA7 variants affect Alzheimer’s disease risk

• Lipid rafts concentrate APP and secretases

Sex Differences in APP Processing

Emerging research shows sex differences in APP metabolism:

• Women may have higher amyloid-beta accumulation at a given age

• Estrogen affects APP processing (protective in pre-menopause)

• ApoE4 effect is stronger in women

• Sex-specific responses to therapy in clinical trials

Regional Vulnerability

APP processing varies across brain regions:

• Entorhinal cortex and hippocampus most vulnerable

• Cerebellum relatively spared until late stages

• Subcortical structures show variable involvement

• Regional differences affect biomarker patterns

Future Directions

Research continues to unravel the complex biology of APP [36]:

• Understanding the physiological functions of APP-derived fragments in aging

• Developing biomarkers for very early detection (pre-plaque)

• Identifying optimal therapeutic targets along the APP processing pathway

• Exploring the relationship between amyloid and other pathological features

• Investigating the role of APP in non-Alzheimer’s disease neurodegenerative diseases

• Targeting APP metabolism in prodromal and pre-symptomatic stages

• Developing personalized medicine approaches based on APP genotype

Conclusion

APP represents a fascinating node in the molecular network of Alzheimer’s disease. While its central role in generating amyloid-beta peptides has made it the focus of decades of research, the complexity of APP biology continues to reveal new insights. Understanding both the pathological and physiological functions of APP will be essential for developing effective therapies for Alzheimer’s disease and related disorders.

See Also

• Alzheimer’s Disease

• Parkinson’s Disease

External Links

• PubMed

• KEGG Pathways

• Allen Human Brain Atlas — APP expression

• BrainSpan Atlas of the Developing Human Brain